The British Neuroscience Association welcomes Roche Diagnostics UK and Ireland as a new Organisational Member
The British Neuroscience Association (BNA) is pleased to welcome Roche Diagnostics (UK & Ireland) as a new Organisational Member.
As part of a growing network of partners spanning neuroscience research, healthcare and industry, Roche Diagnostics joins the BNA in supporting collaboration and shared progress across the neuroscience community.
As the leading provider of in vitro diagnostics in the UK, Roche Diagnostics is committed to improving access to testing throughout the UK and Ireland. By collaborating across the sectors of industry, research, and clinical practice, Roche Diagnostics seeks to transform how diseases are prevented, diagnosed and monitored. Together, through their membership with the BNA they hope to assist the neuroscience research community and broaden access to diagnostics for Alzheimer’s disease.
BNA Organisational Membership will create opportunities for Roche Diagnostics to collaborate and build knowledge exchange and cross-sector dialogue with the neuroscience community. A particular focus will be placed on increasing awareness and understanding of diagnostic innovation - especially blood-based biomarkers - and their potential to support research, clinical decision-making, and earlier diagnosis.
Kate Quinney, Clinical Marketing Partner, Neurology at Roche Diagnostics, commented:
I’m really pleased that we’re partnering with the British Neuroscience Association to strengthen collaboration across academia, industry and healthcare in Alzheimer’s disease. As one of the biggest health challenges facing the world, it’s so important that we work together - building shared understanding of emerging diagnostics and improving access - so that we can make real progress and, ultimately, improve outcomes for patients and their families.
Laura Ajram, Chief Executive of the British Neuroscience Association, said:
The BNA works across disciplines and sectors, and this membership reflects our commitment to embedding cross-sector collaboration within neuroscience. We look forward to working with Roche Diagnostics to strengthen dialogue, share progress in this important diagnostic space, and support greater understanding of how innovation can translate into real-world impact.
The BNA looks forward to working with Roche Diagnostics to further strengthen connections across the neuroscience and healthcare communities, and to support continued progress in research and innovation.
For those interested in learning more about advances in this field, Ashton Harper - Global Medical Affairs Indication Lead, at Roche Diagnostics will be speaking at the upcoming BNA Dementia Masterclass this June, exploring the emerging role of blood-based biomarkers in Alzheimer’s disease and their potential to improve diagnostic accuracy and clinical decision-making.
Ashton Harper
